GB2618727B - Chromosome interaction markers - Google Patents
Chromosome interaction markers Download PDFInfo
- Publication number
- GB2618727B GB2618727B GB2313067.7A GB202313067A GB2618727B GB 2618727 B GB2618727 B GB 2618727B GB 202313067 A GB202313067 A GB 202313067A GB 2618727 B GB2618727 B GB 2618727B
- Authority
- GB
- United Kingdom
- Prior art keywords
- chromosome interaction
- interaction markers
- markers
- chromosome
- interaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000349 chromosome Anatomy 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156659P | 2021-03-04 | 2021-03-04 | |
| US202163282284P | 2021-11-23 | 2021-11-23 | |
| PCT/GB2022/050561 WO2022185062A1 (en) | 2021-03-04 | 2022-03-03 | Chromosome interaction markers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202313067D0 GB202313067D0 (en) | 2023-10-11 |
| GB2618727A GB2618727A (en) | 2023-11-15 |
| GB2618727B true GB2618727B (en) | 2024-07-17 |
Family
ID=80735500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2313067.7A Active GB2618727B (en) | 2021-03-04 | 2022-03-03 | Chromosome interaction markers |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240229135A9 (enExample) |
| EP (1) | EP4301874B1 (enExample) |
| JP (1) | JP2024511292A (enExample) |
| KR (1) | KR20240006020A (enExample) |
| AU (1) | AU2022230780B2 (enExample) |
| BR (1) | BR112023017802A2 (enExample) |
| CA (1) | CA3209544A1 (enExample) |
| ES (1) | ES3029416T3 (enExample) |
| GB (1) | GB2618727B (enExample) |
| HU (1) | HUE071359T2 (enExample) |
| IL (1) | IL304883A (enExample) |
| PL (1) | PL4301874T3 (enExample) |
| TW (1) | TW202302862A (enExample) |
| WO (1) | WO2022185062A1 (enExample) |
| ZA (1) | ZA202309162B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202412610D0 (en) * | 2024-08-28 | 2024-10-09 | Oxford BioDynamics PLC | Screening method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019086898A2 (en) * | 2017-11-03 | 2019-05-09 | Oxford Biodynamics Limited | Genetic regulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198676A1 (en) * | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| GB2626699B (en) * | 2019-05-08 | 2024-11-20 | Oxford BioDynamics PLC | Chromosome Conformation Markers of Prostate Cancer and Lymphoma |
| WO2021228888A1 (en) * | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
-
2022
- 2022-03-02 TW TW111107496A patent/TW202302862A/zh unknown
- 2022-03-03 BR BR112023017802A patent/BR112023017802A2/pt unknown
- 2022-03-03 ES ES22709783T patent/ES3029416T3/es active Active
- 2022-03-03 IL IL304883A patent/IL304883A/en unknown
- 2022-03-03 PL PL22709783.9T patent/PL4301874T3/pl unknown
- 2022-03-03 AU AU2022230780A patent/AU2022230780B2/en active Active
- 2022-03-03 JP JP2023553436A patent/JP2024511292A/ja active Pending
- 2022-03-03 KR KR1020237033851A patent/KR20240006020A/ko active Pending
- 2022-03-03 EP EP22709783.9A patent/EP4301874B1/en active Active
- 2022-03-03 US US18/547,579 patent/US20240229135A9/en active Pending
- 2022-03-03 HU HUE22709783A patent/HUE071359T2/hu unknown
- 2022-03-03 WO PCT/GB2022/050561 patent/WO2022185062A1/en not_active Ceased
- 2022-03-03 CA CA3209544A patent/CA3209544A1/en active Pending
- 2022-03-03 GB GB2313067.7A patent/GB2618727B/en active Active
-
2023
- 2023-09-28 ZA ZA2023/09162A patent/ZA202309162B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019086898A2 (en) * | 2017-11-03 | 2019-05-09 | Oxford Biodynamics Limited | Genetic regulation |
Non-Patent Citations (6)
| Title |
|---|
| DENIS MORGANE ET AL, "How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?", FRONTIERS IN IMMUNOLOGY, Vol. 11, (20200120), Lausanne, CH, ISSN 1664-3224, DOI:10.3389/fimmu.2020.00492, figure 1 * |
| DONGHAI XIONG ET AL, "Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer", ISCIENCE, vol. 9, (20181101), pgs 258-277, US, ISSN 2589-0042, DOI:10.1016/j.isci.2018.10.021, abstract, table S5 * |
| Hunter Ewan ET AL, "Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications", medRxiv,(20211227), pg 21, DOI:10.1101/2021.12.21.21268094 * |
| Kato Shumei ET AL, "Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate", Clinical cancer research, (20170801), pgs 4242-4250, US, DOI:10.1158/1078-0432.CCR-16-3133, Retrieved from the Internet: URL: https://watermark.silverchair.com * |
| Ramadass Aroul ET AL, "EpiSwitch Methodology", https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/EpiSwitch_Methodology-Jun-2020-US.pdf, (202006), Retrieved from the Internet:URL: https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/EpiSwitch_Methodology-Jun-2020-US.pdf, abstract * |
| XUEPING WANG ET AL, "The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy", MOLECULAR CANCER, vol. 19, no. 1, (20200502), DOI: 10.1186/s12943-020-01200-x, abstract * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024511292A (ja) | 2024-03-13 |
| US20240229135A9 (en) | 2024-07-11 |
| BR112023017802A2 (pt) | 2023-12-12 |
| TW202302862A (zh) | 2023-01-16 |
| AU2022230780A1 (en) | 2023-10-12 |
| EP4301874C0 (en) | 2025-04-23 |
| HUE071359T2 (hu) | 2025-08-28 |
| ES3029416T3 (en) | 2025-06-24 |
| EP4301874B1 (en) | 2025-04-23 |
| GB202313067D0 (en) | 2023-10-11 |
| WO2022185062A1 (en) | 2022-09-09 |
| AU2022230780B2 (en) | 2024-05-23 |
| ZA202309162B (en) | 2025-03-26 |
| GB2618727A (en) | 2023-11-15 |
| US20240132959A1 (en) | 2024-04-25 |
| PL4301874T3 (pl) | 2025-06-23 |
| KR20240006020A (ko) | 2024-01-12 |
| CA3209544A1 (en) | 2022-09-09 |
| EP4301874A1 (en) | 2024-01-10 |
| IL304883A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202105969B (en) | Raman markers | |
| GB2617795B (en) | Chromosome interactions | |
| GB202313067D0 (en) | Chromosome interaction markers | |
| GB202114136D0 (en) | Microsatellite markers | |
| GB202019865D0 (en) | No details | |
| GB202012321D0 (en) | No details | |
| ZA202202930B (en) | Diagnostic chromosome marker | |
| GB202020851D0 (en) | Optical markers | |
| HK40102236B (en) | Chromosome interaction markers | |
| HK40102236A (en) | Chromosome interaction markers | |
| GB202102928D0 (en) | Marker | |
| GB202308414D0 (en) | Markers | |
| GB202018037D0 (en) | Planner electrical transfomers | |
| GB202107074D0 (en) | Feature i | |
| GB202113569D0 (en) | Disclosure | |
| GB202113199D0 (en) | Disclosure | |
| GB202110620D0 (en) | Disclosure | |
| GB202109778D0 (en) | Disclosure | |
| GB202109650D0 (en) | Disclosure | |
| GB202109237D0 (en) | Disclosure | |
| GB202101495D0 (en) | Disclosure | |
| GB202101496D0 (en) | Disclosure | |
| GB202100931D0 (en) | Disclosure | |
| GB202100932D0 (en) | Disclosure | |
| CA190094S (en) | Lateral support member |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40102236 Country of ref document: HK |